Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Net Margin (2016 - 2025)

Aytu Biopharma has reported Net Margin over the past 13 years, most recently at 0.41% for Q2 2025.

  • Quarterly Net Margin rose 890.0% to 0.41% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 0.19% through Dec 2025, up 236.0% year-over-year, with the annual reading at 0.93% for FY2025, 603.0% up from the prior year.
  • Net Margin was 0.41% for Q2 2025 at Aytu Biopharma, up from 0.29% in the prior quarter.
  • Over five years, Net Margin peaked at 2.3% in Q3 2024 and troughed at 220.22% in Q1 2022.
  • The 5-year median for Net Margin is 8.4% (2023), against an average of 36.55%.
  • Year-over-year, Net Margin crashed -14801bps in 2021 and then surged 18855bps in 2023.
  • A 5-year view of Net Margin shows it stood at 49.94% in 2021, then surged by 49bps to 25.47% in 2022, then surged by 82bps to 4.48% in 2023, then skyrocketed by 117bps to 0.76% in 2024, then plummeted by -46bps to 0.41% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Net Margin are 0.41% (Q2 2025), 0.29% (Q1 2025), and 0.76% (Q4 2024).